ABSTRACT
Previously, we identified anti-Talin-1 antibodies in the serum of MS. In this case, we measured the serum soluble Talin-1 (sTalin-1) levels by enzyme-linked immunosorbent assay. The serum sTalin-1 levels were significantly higher in 40 patients with MS than in 43 normal controls and in the acute phase of disease than in the remission phase. Interestingly, serum sTalin-1 levels were associated with a sustained increase in disability after MS attack but not with serum anti-Talin-1 antibody levels. sTalin-1 may be a biomarker for the acute phase of MS and may be used for the short-term prognosis of MS.
Subject(s)
Multiple Sclerosis, Relapsing-Remitting/blood , Talin/blood , Adult , Antibodies/blood , Disability Evaluation , Female , Humans , Japan , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/cerebrospinal fluid , Multiple Sclerosis, Relapsing-Remitting/physiopathology , Severity of Illness Index , Statistics as Topic , Statistics, Nonparametric , Talin/cerebrospinal fluid , Talin/immunology , Young AdultABSTRACT
OBJECTIVES: Talin 2 plays an important role in cell adhesion and recycling of synaptic vesicles. To explore the possible role of talin 2 in epilepsy, we designed current study to quantitatively evaluate the changes in talin 2 levels in different epilepsy patients. DESIGN AND METHODS: We measured talin 2 levels in CSF and the serum of postencephalitic epilepsy (PEE) patients (subdivided into drug-refractory PEE-RPEE, and drug-effective PEE-EPEE groups) and acute encephalitis patients (subdivided into acute encephalitis with secondary seizures-AESS, and acute encephalitis without seizures-AE) by enzyme-linked immunosorbent assay. RESULTS: We found that, in RPEE patients, interictal CSF-talin 2 concentrations significantly increased, whereas serum-talin 2 significantly decreased when compared with the AE, AESS, and EPEE groups. CONCLUSIONS: This result suggested that the differential concentration of CSF and serum-talin 2 in the RPEE group is an intractability-related phenomenon that might be involved in the development of RPEE.
Subject(s)
Epilepsy/cerebrospinal fluid , Talin/cerebrospinal fluid , Adolescent , Adult , Child , Drug Resistance , Encephalitis/cerebrospinal fluid , Female , Humans , Male , Middle Aged , Seizures/cerebrospinal fluid , Talin/blood , Young AdultABSTRACT
Proteomic analysis of cerebrospinal fluid (CSF) from patients with temporal lobe epilepsy (TLE) and controls was carried out using two-dimensional gel electrophoresis followed by liquid chromatography electrospray ionization tandem mass spectrometry. Five protein spots showed significant differential expression (p<0.05): vitamin D-binding protein (DBP) was elevated in the CSF of TLE patients whereas cathepsin D, apolipoprotein J, Fam3c, and superoxide dismutase 1 (SOD1) were decreased in the CSF of TLE patients. Additional six protein spots presented only in the CSF of epilepsy patients were identified as tetranectin (TN), talin-2, apolipoprotein E, immunoglobulin lambda light chain (IGL@), immunoglobulin kappa variable light chain 1-5 (IGKV1-5), and procollagen C-endopeptidase enhancer 1 (PCOLCE). Expression of DBP, SOD1 and talin-2 was validated by western blot. Our results may provide better understanding of the pathophysiologic mechanisms underlying epileptogenesis and possible epilepsy biomarkers.
